CSIMarket
 
Staar Surgical Company  (STAA)
Other Ticker:  
 
 
Price: $37.7200 $-0.31 -0.815%
Day's High: $39.15 Week Perf: -2.73 %
Day's Low: $ 37.49 30 Day Perf: 26.2 %
Volume (M): 1,140 52 Wk High: $ 73.13
Volume (M$): $ 43,008 52 Wk Avg: $45.04
Open: $37.82 52 Wk Low: $26.66



 Market Capitalization (Millions $) 1,862
 Shares Outstanding (Millions) 49
 Employees 879
 Revenues (TTM) (Millions $) 310
 Net Income (TTM) (Millions $) 19
 Cash Flow (TTM) (Millions $) -2
 Capital Exp. (TTM) (Millions $) 19

Staar Surgical Company
Staar Surgical Co. is a California-based medical technology company that specializes in developing, manufacturing, and marketing implantable lenses to treat cataracts, refractive errors, and presbyopia. The company was founded in 1982 and has since grown to become a global leader in ophthalmic surgical products, with operations in over 75 countries worldwide.

Staar Surgical's flagship product is the Visian implantable Collamer lens (ICL), which is used to correct nearsightedness, farsightedness, and astigmatism. The ICL is a small, flexible lens that is surgically implanted behind the pupil and in front of the natural lens of the eye. The lens is made of a biocompatible material called collamer that does not cause an immune response and has been found to be safe and effective in over 1 million procedures worldwide.

In addition to the ICL, Staar Surgical sells a range of other ophthalmic surgical products, including intraocular lenses (IOLs), phacoemulsification systems, and micro-invasive glaucoma surgery (MIGS) devices. The company also recently launched a new product called Evo Viva, a next-generation ICL that incorporates advanced optic designs to enhance visual quality and reduce glare and halos.

Staar Surgical has a strong track record of innovation and research, with over 75 patents and patent applications in the United States and internationally. The company has also invested heavily in clinical trials to demonstrate the safety and effectiveness of its products, with more than 20 major clinical studies conducted to date.

Overall, Staar Surgical Co. is a leading player in the global ophthalmic surgical market, with a strong focus on developing innovative and effective treatment options for a wide range of vision conditions. The company is committed to improving patient outcomes through advanced technology and clinical research, and is well-positioned for continued growth and success in the years ahead.


   Company Address: 25651 Atlantic Ocean Drive Lake Forest 92630 CA
   Company Phone Number: 303-7902   Stock Exchange / Ticker: NASDAQ STAA
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Contract

STAAR Surgical Surpasses Milestone with Three Million Implantable Collamer Lenses Sold Globally

Published Mon, Mar 18 2024 11:00 AM UTC

STAAR Surgical, a prominent player in the field of vision correction, recently marked a significant milestone in their business journey. The company announced that it has successfully sold over three million units of its revolutionary Implantable Collamer Lenses (ICLs) worldwide. This noteworthy accomplishment is a testament to the trust and confidence placed in STAAR Surgic...

Management Changes

STAAR Surgical Strengthens Board of Directors with Addition of Industry Titans Arthur Butcher and Wei Jiang, Paving the Way for Global Expansion and Continued Growth

Published Tue, Mar 12 2024 11:00 AM UTC

STAAR Surgical Attracts Top Industry Executives Arthur Butcher and Wei Jiang to its Board of Directors
Lake Forest, Calif. - STAAR Surgical Company (NASDAQ: STAA), a renowned leader in the development, manufacturing, and marketing of the innovative EVO family of Implantable Collamer Lenses (ICL) for the correction of myopia, astigmatism, and presbyopia, proudly announces...

Product Service News

Transforming Vision Correction: STAAR Surgical's Strategic Alliance with SharpeVision

Published Tue, Jan 23 2024 12:00 PM UTC

The demand for innovative vision correction solutions has been on the rise in recent years, as more individuals seek alternatives to glasses and contact lenses. In response to this growing trend, STAAR Surgical Company (NASDAQ: STAA), a renowned developer and manufacturer of Implantable Collamer Lenses (ICL), has entered into a strategic agreement with SharpeVision, a premie...

Management Changes

STAAR Surgical Appoints Accomplished Investor Lilian Zhou to Drive Growth and Achieves Positive ROI

Published Mon, Dec 4 2023 9:05 PM UTC

STAAR Surgical Appoints Lilian Zhou to Its Board of Directors, Achieves Positive Return on Investment
In a recent press release, STAAR Surgical Company has proudly announced the appointment of Lilian Zhou as a new member to its Board of Directors, effective from December 4, 2023. Lilian Zhou, an accomplished investment portfolio manager with experience at highly regarde...

Staar Surgical Company

Staar Surgical Company Beats the Odds: Revenue Surges as Earnings Tumble in Record-Breaking Financial Period

Financial News Report: STAA Delivers Mixed Numbers in Q3 2023
Staar Surgical Company, a leading developer, manufacturer, and marketer of the EVO family of Implantable Collamer Lenses, reported mixed financial results for the third quarter ended September 29, 2023. While revenue showed growth, there were concerns with declining earnings per share (EPS) and a substantial decrease in bottom-line profits.
In terms of revenue, Staar Surgical Company experienced a 5.605% increase, reaching $80.31 million compared to $76.05 million in the previous year. However, EPS plummeted by -52.38% to $0.10 per share, a significant drop from $0.21 in the prior year reporting season.






 

Staar Surgical's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com